Insider Trading Alert - MAR, PFE And XEC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 5, 2014, 233 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.59 to $85,937,500.00.

Highlighted Stocks Traded by Insiders:

Marriott International (MAR) - FREE Research Report

Small Lawrence M who is Director at Marriott International sold 4,953 shares at $53.62 on March 5, 2014. Following this transaction, the Director owned 4,954 shares meaning that the stake was reduced by 49.99% with the 4,953-share transaction.

The shares most recently traded at $54.35, up $0.73, or 1.34% since the insider transaction. Historical insider transactions for Marriott International go as follows:

  • 4-Week # shares sold: 56,213
  • 12-Week # shares sold: 80,662
  • 24-Week # shares sold: 162,790

The average volume for Marriott International has been 2.2 million shares per day over the past 30 days. Marriott International has a market cap of $15.9 billion and is part of the services sector and leisure industry. Shares are up 9.08% year-to-date as of the close of trading on Wednesday.

Marriott International, Inc. operates, franchises, and licenses hotels and timeshare properties worldwide. The company operates through four segments: North American Full-Service, North American Limited-Service, International, and Luxury. The stock currently has a dividend yield of 1.26%. The company has a P/E ratio of 26.9. Currently there are 14 analysts that rate Marriott International a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAR - FREE

TheStreet Quant Ratings rates Marriott International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Marriott International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pfizer (PFE) - FREE Research Report

Susman Sally who is Executive Vice President at Pfizer sold 67,585 shares at $32.59 on March 5, 2014. Following this transaction, the Executive Vice President owned 173,637 shares meaning that the stake was reduced by 28.02% with the 67,585-share transaction.

Dolsten Mikael who is President R&D at Pfizer sold 35,789 shares at $32.58 on March 5, 2014. Following this transaction, the President R&D owned 344,571 shares meaning that the stake was reduced by 9.41% with the 35,789-share transaction.

The shares most recently traded at $32.43, down $0.15, or 0.46% since the insider transaction. Historical insider transactions for Pfizer go as follows:

  • 4-Week # shares sold: 160,000
  • 12-Week # shares sold: 160,000
  • 24-Week # shares sold: 170,000

The average volume for Pfizer has been 26.6 million shares per day over the past 30 days. Pfizer has a market cap of $208.7 billion and is part of the health care sector and drugs industry. Shares are up 6.73% year-to-date as of the close of trading on Wednesday.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The stock currently has a dividend yield of 3.18%. The company has a P/E ratio of 19.8. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PFE - FREE

TheStreet Quant Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cimarex Energy Company (XEC) - FREE Research Report

Bell Stephen P who is Ex VP at Cimarex Energy Company sold 30,625 shares at $115.52 on March 5, 2014. Following this transaction, the Ex VP owned 64,019 shares meaning that the stake was reduced by 32.36% with the 30,625-share transaction.

The shares most recently traded at $112.02, down $3.50, or 3.13% since the insider transaction. Historical insider transactions for Cimarex Energy Company go as follows:

  • 4-Week # shares sold: 24,000
  • 12-Week # shares sold: 43,067
  • 24-Week # shares sold: 50,567

The average volume for Cimarex Energy Company has been 1.0 million shares per day over the past 30 days. Cimarex Energy Company has a market cap of $10.1 billion and is part of the basic materials sector and energy industry. Shares are up 10.26% year-to-date as of the close of trading on Wednesday.

Cimarex Energy Co. operates as an independent oil and gas exploration and production company primarily in Oklahoma, Texas, New Mexico, and Kansas. As of December 31, 2012, the company owned an interest in 4,953 net productive oil and gas wells. The stock currently has a dividend yield of 0.55%. The company has a P/E ratio of 17.9. Currently there are 13 analysts that rate Cimarex Energy Company a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XEC - FREE

TheStreet Quant Ratings rates Cimarex Energy Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, expanding profit margins, good cash flow from operations and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Cimarex Energy Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing